
    
      The study was designed as a double-blind randomized controlled trial, with research assessors
      and patients intended to be blind to the intervention status. The staff members performing
      the assessment were not involved in implementing any aspect of the intervention.128 patients
      were randomized to one of four 12-week individual treatments: metformin (750mg/day), placebo,
      lifestyle intervention plus metformin (750mg/day) or lifestyle intervention plus placebo.
      Medications were provided in double-blind fashion.The assessments include body weight, body
      mass index, waist circumference, fasting glucose, fasting insulin and insulin resistance
      index.
    
  